Profilo
Johan Van Hoof currently works at P.J.A.
Beheer, as Managing Director & Director from 2017 and Ziphius Vaccines NV, as Non-Executive Director.
Posizioni attive di Johan Van Hoof
Società | Posizione | Inizio |
---|---|---|
P.J.A. Beheer
P.J.A. Beheer Financial ConglomeratesFinance P.J.A. Beheer is an investment holding Belgian company. The private company was founded in 2003. Johan Van Hoof has been the CEO of the company since 2017. | Amministratore Delegato | 01/10/2017 |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
P.J.A. Beheer
P.J.A. Beheer Financial ConglomeratesFinance P.J.A. Beheer is an investment holding Belgian company. The private company was founded in 2003. Johan Van Hoof has been the CEO of the company since 2017. | Finance |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | Health Technology |
- Borsa valori
- Insiders
- Johan Van Hoof